Having obtained his doctorate (PhD) in Medicinal Chemistry from Shandong University, China in 2012, Dr. Yingjie Zhang became a faculty member in Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University. Now, Dr. Yingjie Zhang is an Associate Professor in Department of Medicinal Chemistry, Shandong University, Ji’nan, China. From March 2016 to March 2017, Dr. Yingjie Zhang did his visiting scholar research in Department of Pharmacology and Cancer Biology, Duke University. Dr. Yingjie Zhang’s research interests focus on (1) drug discovery targeting epigenetic regulations and post-translational modifications; and (2) Multi-target/multi-mechanism anticancer lead discovery based on drug resistant mechanisms. As first author or corresponding author, Dr. Yingjie Zhang has published more than 60 scientific publications, including nine J Med Chem research paper. The recent paper published in J Med Chem (2019, 62: 3898-3923) was selected as the Supplementary Cover and was recommended by F1000Prime, another paper published in Journal of Medicinal Chemistry (2014, 57: 3324-3341) was highlighted by SciBX (Science–Business eXchange) as a weekly news in the field of anticancer therapeutics and was selected by Global Medical Discovery website as a key drug discover article. One research paper was published as the issue cover paper of Chemical Biology & Drug Design. Dr. Yingjie Zhang was awarded the 17th Chinese Pharmaceutical Association-Servier Prize for Young Investigators in Medicinal Chemistry in 2014. Now, Dr. Yingjie Zhang serves as an Editorial Board Member of J Med Chem, Anti-Cancer Agent. ME, Drug Discov Ther, and as reviewers of over 50 academic journals, including J Med Chem, Trends Pharmacol. Sci, Eur J Med Chem, Med Res Rev, etc.